Camurus ABCAMRF -3.57%83 EBIT per Share is $1.54 as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $69.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,181 Biotechnology companies, Camurus AB ranks better than 99.41% on this metric.
Camurus AB's EBIT per Share for the
three
months ended in Mar. 2026 was $0.33.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.54.
During the past 12 months, the average EBIT per Share Growth Rate of Camurus AB was 27.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 126.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Camurus AB's EBIT per Share or its related term are showing as below:
CAMRF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.3 Med: 13.4 Max: 126.9
Current: 126.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Camurus AB was 126.90% per year. The lowest was -43.30% per year. And the median was 13.40% per year.
CAMRF's 3-Year EBIT Growth Rate is ranked better than 99.41% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs CAMRF: 126.90
Camurus AB's EBIT for the
three
months ended in Mar. 2026 was $19.9 Mil.
Camurus AB (OTCPK:CAMRF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Camurus AB EBIT per Share Related Terms
Camurus AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Camurus AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a EBIT per Share of $1.54 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #7 out of 1181 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Camurus AB's EBIT per Share too high?
Camurus AB's current EBIT per Share is $1.54. The Biotechnology industry median EBIT per Share is 15.50. Camurus AB's value of $1.54 is 90.1% below this industry median. Based on the distribution chart, Camurus AB ranks #7 out of 1181 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #7 out of 1181 companies for EBIT per Share. This places Camurus AB in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. Camurus AB's value of $1.54 is 90.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current EBIT per Share of $1.54 is 90.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current EBIT per Share is $1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $69.05, compared to a current price of $54.00 — trading 21.8% below its estimated fair value. The current EBIT per Share is $1.54 and 90.1% below the Biotechnology industry median of 15.50. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EBIT per Share is $1.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 21.8% below its estimated GF Value™ of $69.05.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
EBIT per Share: $1.54
GF Value™: $69.05 vs. price of $54.00 (21.8% below fair value)
Industry Position: 90.1% below the Biotechnology median (#7 of 1181)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score
Get the complete analysis for CAMRF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
